eligibility_summary
MM patients able to adhere to visits, bone marrow procedures, and first‑cycle hospitalization. Requires measurable disease, ECOG 0–2, 1–3 prior lines incl. lenalidomide and an anti‑CD38 mAb (≥2 cycles), ≥minimal response to any prior therapy, and progression during/after last therapy or no response. Excludes active/uncontrolled infection, CNS MM or major CNS disease, prior BCMA TCE/CAR‑T, prior allo SCT or auto SCT <3 months. Other criteria apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 randomized, open-label RRMM trial (withdrawn) comparing alnuctamab vs standard regimens. Alnuctamab (BMS-986349/CC-93269) is a bispecific T-cell engager antibody that binds BCMA on myeloma cells and CD3 on T cells to redirect cytotoxic killing. Comparators: pomalidomide (IMiD, cereblon modulator causing IKZF1/3 degradation, enhances T/NK activity), daratumumab (anti-CD38 IgG1, depletes CD38+ cells via ADCC/CDC/ADCP and apoptosis), elotuzumab (anti-SLAMF7, activates NK cells and mediates ADCC against SLAMF7+ myeloma), carfilzomib (irreversible proteasome inhibitor targeting 20S chymotrypsin-like activity, inducing proteotoxic apoptosis), dexamethasone (glucocorticoid, lympholytic, pro-apoptotic via GR). Targets/pathways: BCMA+ plasma cells, CD3 T cells, CD38, SLAMF7, proteasome, cereblon/IKZF axis, NK activation, glucocorticoid receptor signaling.